MORRISVILLE – Liquidia Corporation (Nasdaq:LQDA) has appointed Rajeev Saggar, M.D., to the position of chief medical officer.

Dr. Saggar will oversee the publicly-traded pharma company’s research, clinical development, and medical and regulatory affairs for the company, as of July 18, 2022, the company announced in a statement this week.

““We are excited to add a leader of Dr. Saggar’s caliber to our team as we prepare for the launch of YUTREPIA™ (treprostinil) inhalation powder upon receipt of final FDA approval,” said Roger Jeffs, Liquidia’s CEO.

In Dr. Saggar’s most recent role as the vice president of clinical development at Theravance Biopharma, he oversaw the phases of clinical development across the firm’s respiratory disease portfolio including COVID-19.

Previously, Saggar served as the interim chief of the division of pulmonary critical care at the University of Arizona, College of Medicine, Phoenix and the medical director of the Pulmonary Hypertension and Fibrosis Programs and Lung Transplant Program at Banner University Medical Center, Phoenix.

The company’s lead therapy, YUTREPIA™ (treprostinil) inhalation powder, is an investigational dry powder that is delivered through a palm-sized device.  The FDA issued a tentative approval in November 2021, according to the company’s statement, indicated for the treatment of pulmonary arterial hypertension.  The therapy was previously known as “LIQ861.”

Earlier this year, the company named Jeffs CEO and expanded a credit facility.

Triangle biopharma Liquidia doubles debt facility, names new CEO